Mode
Text Size
Log in / Sign up
N/A N=117 Randomized Double-blind Basic Science

Happy Mother - Healthy Baby: Supplement Study on Biological Processes Underlying Anxiety During Pregnancy

Anxiety

Enrolled (actual)
117
Serious AEs
36.8%
Results posted
Nov 2024
Primary outcome: Primary: Peripheral Markers of Inflammation — 17.09; 20.22; 14.79; 11.78 pg/ml

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins Bloomberg School of Public Health
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Peripheral Markers of Inflammation
17.09; 20.22; 14.79; 11.78; 12.12; 11.65
PRIMARY
Allopregnanolone Levels and Anxiety Symptoms Across the Peripartum
-0.3796214; -0.3828328; -0.2820709; 2.825177; 3.149545; 3.048794
PRIMARY
Allopregnanolone Levels Predicting Postpartum Depression
-0.004127186; -0.8292861; -0.4591347; -0.08843005; -0.1739193
PRIMARY
Allopregnanolone (ALLO) and Immune Function
0.607838873; 0.508436643; 0.731221724; 0.943495625; 0.962951805; 0.32767424
SECONDARY
Birth Outcomes
5; 3; 3; 5; 6; 8
SECONDARY
Infant Neuro-development Using Ages & Stages Questionnaire, Third Edition (ASQ-3)
0; 0; 0; 3; 2; 1

Summary

As a supplement to the ongoing randomized evaluation of the Cognitive Behavioral Therapy (CBT) anxiety prevention intervention in Pakistan (R01-MH111859), the investigators propose to explore potential biological mechanisms (related to inflammation and endocrine functioning) of antenatal anxiety through additional data collection with 300 pregnant women.

Eligibility Criteria

Inclusion Criteria

  • ability to understand spoken Urdu
  • pregnant, ≤22 weeks' gestation
  • age ≥18 years
  • residence ≤20 km of Holy Family Hospital
  • intent to reside in the study areas until the completion of the study

Exclusion Criteria

  • Current anemia
  • Current major depressive episode (MDE on SCID) or life-threatening health conditions including e.g. active severe depression or suicidal ideation
  • Self-report of past or current significant learning disability
  • Self-report of past or current psychiatric disorder (e.g. bipolar disorder or schizophrenia) or psychiatric care (e.g. current use of anxiolytic drug and/or other psychotropic drug)
  • medical disorders or severe maternal morbidity that require inpatient management that would preclude participation (101)
  • ICU admission indicated by diagnosis (not only for assessment)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04566861). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search